Speaker Profile

Ph.D., CTO & Co-Founder, Day Zero Diagnostics

Biography
Miriam Huntley is the CTO and a Co-Founder of Day Zero Diagnostics, a healthcare startup spun out of Harvard University to develop a genomic sequencing-based rapid diagnostic for bacterial infections. As CTO of the company, Dr. Huntley leads the machine learning, computational biology, and software engineering development. Her work at the startup has earned her recognition as a TedMed Hive Innovator and as one of MedTech Boston 40 under 40 Healthcare Innovators. She received her BSc from MIT in Physics and her PhD in Applied Math at Harvard University, where she developed data analysis methods and theoretical models for problems in biology. Her research helped to discover fundamental structures in the three-dimensional folded genome, and has been covered widely in the public media by outlets such as NPR, Forbes, and the Smithsonian Museum.


Clinical Dx Showcase:
Day Zero Diagnostics

Day Zero Diagnostics is an infectious disease diagnostics company using whole-genome sequencing and machine learning to combat the rise of antibiotic-resistant infections.

Definitive Clonality Determination in Hospital-acquired Infection
Introducing epiXact, a rapid WGS-based service that provides hospitals with definitive and accurate answers for infection transmission investigations. epiXact computes pathogen relatedness at the single nucleotide level using a high-resolution SNP based pipeline enabling the highest confidence in clonality determination.

 Session Abstract – PMWC 2022 Silicon Valley


The PMWC 2022 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.

- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Nerodegenerative